TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~1. Adults 18-75 years of age;~2. Current diagnosis of unipolar major depressive disorder (MDD) without psychosis as confirmed by structured clinical interview for DSM-IV disorders;~3. A score of \>= 9 on the Montgomery-Åsberg Depression Rating Scale (MADRS);~4. Documented (i.e., chart review) lifetime failure to respond to \>=3 adequate dose/duration antidepressant treatment trials, ≥1 medication failure in the current depressive episode;~5. Good command of the English language.~Exclusion Criteria~1. Meets criteria for any DSM-IV diagnosis for schizophrenia, bipolar, schizoaffective, obsessive-compulsive, personality, or panic disorders;~2. Any recent (within past 12 months) history of substance dependence or abuse (except tobacco), determined by reported history or urine drug screen;~3. Ability to become pregnant and not using effective contraception;~4. Contraindication against the use of nitrous oxide:~   1. Pneumothorax~  2. Bowel obstruction~  3. Middle ear occlusion~  4. Elevated intracranial pressure~  5. Chronic cobalamin and/or folate deficiency treated with folic acid or vitamin B12~  6. Pregnant patients~  7. Breastfeeding women~5. Inability to provide informed consent;~6. Any other factor that in the investigators' judgment may affect patient safety or compliance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1. 25% nitrous oxide, 25% nitrogen, 25% oxygen (Type: EXPERIMENTAL): Participants will be studied for 14 visits over approximately 18 weeks. The participants will receive 1 hour-long gas inhalation mixtures at 3 different times, which are randomly assigned.
- 2. 50% nitrous oxide, 50% oxygen (Type: EXPERIMENTAL): Participants will be studied for 14 visits over approximately 18 weeks. The participants will receive 1 hour-long gas inhalation mixtures at 3 different times, which are randomly assigned.
- 3. Placebo gas: 50% nitrogen(inert), 50% oxygen (Type: PLACEBO_COMPARATOR): Participants will be studied for 14 visits over approximately 18 weeks. The participants will receive 1 hour-long gas inhalation mixtures at 3 different times, which are randomly assigned.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with known sarcoidosis 21.~* Age 18 or greater~* Patients with documented pulmonary hypertension with a PA mean \> 25 mm Hg as measured by cardiac catheterization within six months of entry into the study. Pulmonary artery occluding pressure and or left ventricular end diastolic pressure must be less than 15 mm Hg.~* Patients with WHO class II or III~* Six minute walk distance of between 100 to 500 meters~* Patients on stable immunotherapy for their sarcoidosis, including prednisone, methotrexate, azathioprine, hydroxychloroquine, cyclophosphamide, thalidomide, and/or infliximab~* Patients able to provide written consent~Exclusion Criteria:~* Patients on pulmonary vasodilator drugs (flolan, remodulin, bosentan, sildenafil) n the prior 28 days. Patients on stable dose of calcium channel blocker for more than 1 month prior to right heart catheterization can be continued on the calcium channel blocker.~* Patients with severe airway obstruction as defined by FEV1/FVC of less than 35%~* Patients with World Health Organization (WHO) class IV status.~* Patients who are pregnant or breast feeding~* Patients with significant left ventricular dysfunction with a left ventricular ejection fraction of less than 35%~* Cardiac index \< 2.0 liters and/or right atrial pressure \>15 mm Hg~* Significant liver dysfunction not due to sarcoidosis.~* Patients with severe other organ disease felt by investigators to impact on survival during the course of the study.~* Patients unable to perform the 6 minute walk study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bosentan for 16 weeks (Type: ACTIVE_COMPARATOR): Active drug
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (MK0518-018 EXT2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be HIV positive with HIV RNA values that are within ranges required by the study~* Patient must have documented failure of certain antiretroviral therapy~* Patient must be on the same antiretroviral therapy for at least the past two months~Exclusion Criteria:~* Patient is less than 16 years old~* Additional study criteria will be discussed and identified by the study doctor

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): raltegravir potassium
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stable without clinically significant disease~Exclusion Criteria:~* Use of NSAID within 2 weeks~* Type 1 or 2 DM~* GI disorder

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): PN400 + ASA
- 2 (Type: PLACEBO_COMPARATOR): Placebo + ASA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ph II Bevacizumab + Etoposide for Pts w Recurrent MG

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pts have confirmed diagnosis of recurrent/progressive WHO gr III \& IV MG~* Age \>18 rs~* Interval of \>4 wks since prior surgery~* Interval of \>4 wks since prior XRT/chemo, unless there is unequivocal evidence of progressive disease \& pts have recovered from all anticipated toxicity of most recent therapy;~* Karnofsky performance status score \>60~* Hematocrit \>29 percent, ANC \>1,500 cells/microliter, platelets \>100,000 cells/microliter~* Serum creatinine \<1.5 mg/dl, BUN \<25 mg/dl, serum SGOT \& bilirubin \<1.5 x ULN~* For pts on corticosteroids, they have been on astable dose for 1wk prior to entry~* Signed informed consent approved by IRB prior to pt entry~* If sexually active, pts must agree to take contraceptive measures for duration of treatments.~Exclusion Criteria:~* Prior therapy w either bevacizumab/etoposide~* \>3 prior recurrences~* Pregnancy/breast feeding~* Co-medication w immuno-suppressive agents other than corticosteroids including but not limited to cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil~* Evidence of CNS hemorrhage on baseline MRI on CT scan~* Pts who require therapeutic anti-coagulation~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring IV antibiotics \& psychiatric illness/social situations that would limit compliance w study requirements, or disorders associated w significant immunocompromised state~* Pts w another primary malignancy that has required treatment \<past year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab + Etoposide (Type: EXPERIMENTAL): Grade III and IV patients will receive: Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If patient tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D Supplementation and Acute Respiratory Infection in Older Long-Term Care Residents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 60+ years~* Resides in nursing home~Exclusion Criteria:~* Terminal illness (expected survival \<6 months)~* Anticipated discharge within 12 months~* Unable to take whole or crushed tablets~* Active cancer, except squamous/basal cell carcinoma~* Severe malnutrition (body mass index \<18 kg/m2)~* Current immunosuppressive medications (including corticosteroids)~* Renal failure (estimated glomerular filtration rate \< 15 mL/min/1.73m2)~* Currently taking \>1,000 IU/d vitamin D supplementation~* History (or strong family history) of kidney stones~* History of sarcoidosis or other granulomatous disorders associated with hypercalcemia~* Elevated baseline hypercalcemia (albumin-adjusted serum calcium \>10.5 mg/dL)~* Baseline serum 25OHD level ≥ 100 nmol/L~* Inability to provide informed consent and no available healthcare legally authorized representative~* Inability of participant or legally authorized representative to speak/understand English

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High Dose Vitamin D (Type: EXPERIMENTAL): 100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day.
- Standard Dose Vitamin D (Type: ACTIVE_COMPARATOR): 12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Give their signed written informed consent to participate~2. Are at least 40 years of age and no older than 80 years~3. COPD patients who are symptomatic~4. Must be receiving one or more inhaled bronchodilators as maintenance therapy~Exclusion Criteria:~1. Current diagnosis of asthma,~2. COPD due to α1-Antitrypsin Deficiency~3. Known active tuberculosis, lung cancer, cystic fibrosis, significant bronchiectasis, Pulmonary resection or Lung Volume Reduction Surgery during the past 6 months~4. Long-term-oxygen therapy (≥ 12 hours a day).

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- BFF MDI 320/9.6 μg (Type: EXPERIMENTAL): Budesonide and Formoterol Fumarate Inhalation Aerosol 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
- BFF MDI 160/9.6 μg (Type: EXPERIMENTAL): Budesonide and Formoterol Fumarate Inhalation Aerosol-80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
- FF MDI 9.6 μg (Type: EXPERIMENTAL): Formoterol Fumarate Inhalation Aerosol-4.8 μg per actuation MDI/ 120 inhalations Taken as 2 inhalations BID
- BD MDI 320 μg (Type: EXPERIMENTAL): Budesonide inhalation Aerosol 160 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID
- Symbicort® TBH 400/12 μg (Type: OTHER): Symbicort Turbuhaler 400/12 μg Taken as 2 inhalations BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~A patient is eligible for inclusion in this study if all of the following criteria apply:~* Age: 18-75 years of age~* Surgery: craniotomy under general anesthesia.~* American Society of Anesthesiologists (ASA) Status: ASA: I, II, or III~* Language: Fluent in the English language~* Informed Consent: Written informed consent must be obtained.~Exclusion Criteria:~A patient will not be eligible for inclusion in this study if any one or more of the following criteria apply within thirty days of patient enrollment in this clinical trial:~* Medical: Any condition that may impair a patient's ability to complete any of the study assessments or confound interpretation of results.~* Hypersensitivity: Patient has a known immediate or delayed hypersensitivity reaction or known idiosyncrasy to any of the two study medications, ondansetron, or aprepitant.~* Other Drugs: Patients should not be taking medications with known antiemetic properties (phenothiazines, butyrophenones, antihistamines), nor should they receive metoclopramide, or other antiemetics preoperatively or 12 hours before the scheduled surgical procedure.~* Pregnant or lactating females: A pregnancy test will be performed within 24 hours of entering the study for females of childbearing potential.~* Substance Abuse: Clinically significant abuse of substances (alcohol, illicit or prescribed medications) such that the patient is unable to provide informed consent or reliably complete any of the study assessments.~* Psychiatric Disease: History of a psychiatric illness that may impair the patient's ability to provide informed consent or complete any of the study assessments.~* Nausea verbal rating score (VRS): A VRS nausea score \> 3 (scale 0-10) in the preoperative holding area before pretreatment with the study medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Aprepitant 40 mg preoperatively + dexamethasone 10 mg after induction of anesthesia
- 2 (Type: ACTIVE_COMPARATOR): Ondansetron 4 mg within 30 min of the end of surgery + Dexamethasone 10 mg after induction of anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Episodic Acyclovir Therapy for Genital Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males presenting at the primary health care clinic with a genital ulcer~* Age 18 years or older~* Willing and able to give informed consent~* Willing to be tested for HSV and HIV~* Willing and able to comply with the study protocol including follow-up visits~* Willing to accept therapy by chance~Exclusion Criteria:~* Extensive ulceration~* Ulceration \>1 month~* History of adverse reaction to acyclovir~* Taking suppressive therapy for genital herpes~* History of renal insufficiency or proteinuria

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Does the Addition of Epinephrine Prolong the Duration of Spinal Anesthesia for Repeat Cesarean Section?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Non-emergent repeat cesarean section~* Neuraxial anesthesia as the planned primary anesthetic~* Informed consent obtained~* Females age 18-50~Exclusion Criteria:~* Emergency cesarean section~* Anesthetic other than neuraxial~* Allergy to local anesthetics, morphine, or epinephrine~* Pre-existing sensory/motor deficit

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Low-dose epinephrine (Type: EXPERIMENTAL): 100micrograms of epinephrine group
- High-dose epinephrine (Type: EXPERIMENTAL): 200micrograms of epinephrine group
- No epinephrine (Type: PLACEBO_COMPARATOR): 0.2ml saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients ≥ 18 years of age.~2. ECOG 0, 1, or 2.~3. Have been diagnosed with Ph+ CML-CP and receiving imatinib therapy.~4. Patients with suboptimal molecular response to imatinib treatment continued for at least 18 months (first line therapy)~   Suboptimal molecular response defined as all of the following conditions:~  1. Patients who have achieved CCyR (0% Ph+ chromosomes).~  2. Patients who don't achieve MMR (MMR defined as BCR-ABL/ABL ratio of ≤ 0.1% on the International Scale as detected by RQ-PCR).~   The treatment with imatinib defined as:~   Dose of 300 mg or higher daily must be maintained for a minimum of 3 months prior to study entry.~5. Patients who meet the following laboratory tests criteria:~   1. total bilirubin \< 1.5 x ULN,~  2. SGOT and SGPT \< 2.5 x ULN,~  3. creatinine \< 1.5 x ULN,~  4. Serum amylase and lipase ≤ 1.5 x ULN,~  5. Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related.~  6. Serum potassium, phosphorus, magnesium and calcium ≥ LLN or correctable with supplements prior to the first dose of study drug.~6. Written informed consent prior to any study related screening procedures being performed.~Exclusion Criteria:~1. Prior accelerated phase or blast crisis CML.~2. Previously documented T315I mutations.~3. Presence of chromosomal abnormalities other than Ph+.~4. Previous treatment with any other tyrosine kinase inhibitor except imatinib.~5. Impaired cardiac function including any one of the following:~   1. Complete left bundle branch block~  2. Congenital long QT syndrome or family history of long QT syndrome~  3. History of or presence of significant ventricular or atrial tachyarrhythmias~  4. Clinically significant resting brachycardia (\<50 bpm)~  5. QTcF \> 450 msec on screening ECG~  6. Use of a ventricular-paced pacemaker~  7. Myocardial infarction during the last 12 months~  8. Other clinically significant heart disease (e.g. congestive heart failure, uncontrolled hypertension, unstable angina).~6. Treatment with strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St John's Wort), and the treatment cannot be discontinued or switched to a different medication prior to starting study drug. See Section 6.4.3 for complete list of these medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nilotinib (Type: EXPERIMENTAL): 400 mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telephone Counseling: Men With Prostate Cancer & Partners

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Receiving treatment for prostate cancer~* Over 21 years~* Access to and ability to talk on the phone~* Speaks English and has a partner to participate with him.~* Partners are anyone who the man chooses (friend or relative) who is over 21 years, English speaking and has access and ability to talk on the phone.~Exclusion Criteria:~* under 21 years~* Does not speak English

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telephone Interpersonal Counseling (Type: EXPERIMENTAL): Telephone delivered interpersonal counseling support intervention. Intervention was for 8 weeks. Participants were called on the telephone each week for about 30 minutes.
- Telephone delivered education only (Type: ACTIVE_COMPARATOR): Telephone delivered education only. Educational topics included prostate cancer health, side effects, physical activity, diet. Participants were called on the telephone each week for about 30 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete